Mebias Discovery, Inc Employee Directory

Biotechnology ResearchPennsylvania, United States2-10 Employees

Mebias Discovery, Inc. is a Philadelphia-based biotechnology company focused on discovering drugs that target G-protein coupled receptors. The firm aims to identify next-generation GPCR therapeutics with fewer on-target side effects by examining how receptors move and signal. Its platform relies on validated assays that link ligand-induced receptor conformations to pharmacologic outcomes, and the team is described as small and science-driven.

Its initial focus areas include CNS-related conditions, pain, opioid use disorder, as well as metabolic and inflammatory disorders. A lead mu-opioid receptor program, MEB-1170, is presented as a differentiated biased agonist with a profile that reportedly avoids key liabilities such as respiratory depression, tolerance, and abuse potential. Public notes indicate MEB-1170 entered Phase I clinical development in late 2022, and the company publicly seeks co-development or licensing arrangements and collaborations to advance additional targets.

Sign up for free to view info

Company overview Email format